Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Medulloblastomas, brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now analyzed the genetic changes of ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration ...

Sancho and his team used models that mimic human cancer to test a dendritic cell vaccine. As a result, T cells were activated, and tumors significantly shrunk. When researchers injected previously ...

Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...

giant cell tumor of bone (GCT), aneurysmal bone cyst (ABC), tenosynovial giant cell tumor (TGCT), and giant cell reparative granuloma (GCRG). Results: Immunohistochemical (IHC) analysis reveals strong ...

In contrast, this dendritic cell-based immunotherapy aims to induce a new, specific immune response against the tumor." Describing the strategy, study co-supervisor Stefanie Wculek—formerly at ...